Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Psoriasis
Interventions
DRUG

CTA018 cream

Trial Locations (16)

10016

New York University Medical Center, New York

10029

Mount Sinai School of Medicine, New York

14221

Buffalo Medical Group PC, Williamsville

19103

Paddington Testing Co., Philadelphia

27157

Wake Forest University Health Sciences, Winston-Salem

29607

Palmetto Clinical Trial Services LLC, Greenville

29621

Radiant Research Inc., Anderson

44106

University Hospitals of Cleveland, Cleveland

45249

Radiant Research, Cincinnati

55905

Department of Dermatology, Mayo Clinic, Rochester

60611

Northwestern University, Chicago

66215

Radiant Research, Kansas City, Overland Park

72205

Dermatology Research of Arkansas PLLC, Little Rock

85710

Radiant Research, Tucson

02215

Mass General/ Brigham & Women's, Boston

08903

UMDNJ-Robert Wood Johnson Medical School, New Brunswick

All Listed Sponsors
lead

OPKO Health, Inc.

INDUSTRY

NCT00384098 - Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis | Biotech Hunter | Biotech Hunter